Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 439

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 439
---
 is committed for a minimum period of 12years ,

corresponding to a commitment of $ 0.2 billion. The lease includes two extension options of five years each.

During 2024 , Sanofi signed a 12-year lease in France which will take effect in 2027, representing a commitment of € 0.2 billion.

(b) These comprise irrevocable commitments to suppliers of (i) property, plant and equipment, net of down-payments (see Note D.3.) and (ii) goods and

services. As of December 31, 2023 , irrevocable commitments amounted to € 6,141million given (including € 754million related to Opella) and € 550million

received (zero related to Opella).

(c) Irrevocable purchase commitments given as of December 31, 2024 include € 749million of commitments to joint ventures. This line also includes (i) the

commitment to EUROAPI as described in Note D.1. and amounting to € 535million as of December 31, 2024, and (ii) commitments related to long-term

renewable energy purchase contracts lasting between 15 and 20 years giving rise to the physical supply of electricity mainly in France for an estimated

total annual volume of 329 GWh.

(d) Commitments related to research and development, and other commitments, amounted to € 381million as of December 31, 2023 .

(e) This line only includes contingent milestone payments on development projects in progress. The equivalent amount as of December 31, 2023 was

€ 4,886million .

In pursuance of its strategy, Sanofi may acquire technologies and rights to products. Such acquisitions may be made in various

contractual forms: acquisitions of shares, loans, license agreements, joint development, and co-marketing. These arrangements

generally involve upfront payments on signature of the agreement, development milestone payments, and royalties. Some of

these complex agreements include undertakings to fund research programs in future years and payments contingent upon

achieving specified development milestones, the granting of approvals or licenses, or the attainment of sales targets once a

product is commercialized.

| SANOFIFORM 20-F2024 | F-79 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

The “Research and development license agreements” line comprises future service commitments to fund research and development or technology, and contingent